# Ivoryon Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ivoryon-therapeutics

- Industry: Biotechnology
- Headquarters: Halle, Germany
- Website: www.vivoryon.com/
- Total disclosed funding: $86M
- Latest round: Series B (Jan 4, 2012)
- Investors on record: 10

## About

Based in Halle, Germany, and founded in 1997, Ivoryon Therapeutics AG, formerly Probiodrug AG operates as a biopharmaceutical company that specializes in the development of innovative small-molecule drugs. Probiodrug leverages its expertise with novel targets, such as Glutaminyl Cyclase (QC) and Cyclin-Dependent Kinase 9 (CDK9), to develop drugs for the treatment of widespread diseases such as Alzheimer’s disease and chronic inflammation. In January 2012, BB Biotech Ventures, Biogen Idec New Ventures, Edmond de Rothschild Investment Partners, GoodVent, HBM Partners, Life Sciences Partners, TVM Capital, and Wellington Management completed a USD 20 million Series C round of financing of Probiodrug AG. In November 2014, Probiodrug AG raised EUR 22.5 million through an IPO in which 1.5 million shares were sold at EUR 15.25 per share.

## Funding rounds

- Series B, Jan 4, 2012, $19M — TVM Capital Life Science, HBM Partners, Andera Partners, EQT Life Sciences, BMP, BB Biotech, Wellington Management, Biogen Idec New Ventures
- Series B, Nov 2, 2009, $54M — CFH Management, HBM Partners, Andera Partners, EQT Life Sciences, BMP, BB Biotech, Biogen Idec New Ventures, TVM Capital
- Series C, Jun 15, 2006, $13M — CFH Management, BMP

## Investors

- CFH Management (https://capitalatlas.ai/funds/cfh-management) — Series C, Series B
- BMP (https://capitalatlas.ai/funds/bmp) — Series C, Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B
- BB Biotech (https://capitalatlas.ai/funds/bb-biotech) — Series B
- Biogen Idec New Ventures (https://capitalatlas.ai/funds/biogen-idec-new-ventures) — Series B
- TVM Capital (https://capitalatlas.ai/funds/tvm-capital) — Series B
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series B
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B